Anti-Hu CD180 Purified Low Endotoxin

Anti-Hu CD180 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD180
Clone
G28-8
Format
Purified Low Endotoxin
Reactivity
Human
Application
IP, FC (QC tested), FUNC
Variant
0.1 mg
12-637-C100
Out of stock
Variant
0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody G28-8 recognizes CD180, a 95-105 kDa TLR-like glycoprotein expressed on peripheral blood monocytes and dendritic cells, mantle zone B cells and marginal zone B cells, but very weakly on germinal center B cells.
Application
IP, FC (QC tested), FUNC
Reactivity
Human
Immunogen
Human tonsillar B cells
Other names
LY64, Ly78, RP105
Preparation
Purified by protein-A affinity chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis. 2001 Dec;60(12):1137-40.
PubMed
Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol. 2007 Aug;82(2):265-71.
PubMed
Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 2003 Aug 15;102(4):1374-80.
PubMed
Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun;6(6):571-8.
PubMed

Product specific references:

Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA: Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 1988 Jun 15;140(12):4071-8.
PubMed
Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, Valentine MA: Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol. 1989 Dec 15;143(12):3873-80.
PubMed
Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA: Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol. 2003 Jun 15;170(12):6065-72.
PubMed
Variant
0.1 mg
12-637-C100
Out of stock
Variant
0.1 mg
11-261-C100
In stock